Core Viewpoint - The company has received approval for the injectable Nicorandil from the National Medical Products Administration, which is intended for the treatment of unstable angina pectoris, enhancing its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently obtained the drug registration certificate for injectable Nicorandil [1] - The approval of injectable Nicorandil will further enrich the company's formulation varieties [1] Group 2: Market Considerations - The sales performance of the newly approved drug will depend on various internal and external environmental changes, indicating a level of uncertainty [1] - The company commits to timely information disclosure based on subsequent developments [1]

Core Viewpoint - The announcement details the pledge of shares by a major shareholder, Cai Nanguai, which exceeds 80% of his holdings, raising potential concerns for investors regarding the company's financial stability and governance [1][8]. Shareholder Pledge Basic Situation - Cai Nanguai holds 67,512,703 shares, making him the largest shareholder but not the controlling shareholder. He has signed a commitment to waive voting rights on his remaining shares [1]. - The pledged shares do not involve any major asset restructuring or performance compensation obligations [1]. Cumulative Pledge Situation - As of the announcement date, the pledged shares include those of Cai Nanguai and his concerted actions, with specific details on the number of shares pledged and their status [2]. Financing and Use of Pledged Shares - Part of the financing from the pledged shares will be used to provide loans to the company to support its operations, while the remainder is for personal funding needs [3][6]. - Cai Nanguai and his concerted actions have no upcoming pledge financing due within the next six months or one year, indicating a stable financial situation [3]. Risk Management and Control - Cai Nanguai's high proportion of pledged shares is primarily to support company development and personal funding needs. He has a good credit status and repayment capability, with no debt repayment risk [7]. - The company’s control has changed, but this will not affect its operations or governance [5][8]. Guarantees and Loans - Cai Nanguai has provided guarantees for credit limits totaling 60 million yuan to banks, with no counter-guarantees from the company or its subsidiaries, incurring no related costs [7]. - He has also provided loans to the company up to 160 million yuan at an annual interest rate of 3.0%, calculated based on actual borrowing amounts and days used [7].

Company Overview - *ST Sailong (SZ 002898) announced that as of the date of the announcement, Cai Nanguo has pledged a total of approximately 67.51 million shares, which accounts for 100% of his holdings [1] - As of the report date, *ST Sailong has a market capitalization of 2.4 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of *ST Sailong is as follows: pharmaceutical manufacturing accounts for 59.82%, the electronics industry accounts for 39.78%, and other businesses account for 0.4% [1]

证券代码：002898 证券简称：*ST赛隆 公告编号：2025-089 1.公司持股5%以上股东蔡南桂先生及其一致行动人质押的股份数量占 其所持公司股份数量比例已超过80%，请投资者注意相关风险。 赛隆药业集团股份有限公司（以下简称"公司"）于近日接到公司持 股5%以上股东蔡南桂先生的通知，获悉蔡南桂先生将其持有的本公司股份 办理了质押手续，具体事项如下： 一、股东股份质押基本情况 | 股 东 名 称 | 是否 为控股 股 东或第一 大股 东及 其一致行动 人 | 本次质押 数量 （股） | 占其所 持股份 比例 | 占公司 总股本 比例 | 是否为限 售股（如 是，注明 限 售 类 型） | 是否为 补充质押 | 质押起 始日 | 质押 到期 日 | 质 权 人 | 质 押 用 途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 蔡南桂 | 是 | 67,512,70 3 | 100% | 38.36% | 是（高管锁 定股） | 否 | 2025.11. 04 | 解除质 押登记 之日 | 海南启航 星途科技 ...

Company Overview - *ST Sailong (SZ 002898) announced on October 28 that its fourth board meeting was held on October 27, 2025, in Changsha, Hunan Province, to review the proposal for the third quarter report of 2025 [1] - As of the report, *ST Sailong has a market capitalization of 2.5 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of *ST Sailong is as follows: pharmaceutical manufacturing accounted for 59.82%, the electronics industry for 39.78%, and other businesses for 0.4% [1]

Group 1 - *ST Sailong reported a revenue of approximately 200 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 8.56% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 40.4 million yuan [1] - The basic earnings per share showed a loss of 0.2295 yuan [1] Group 2 - As of the report, *ST Sailong's market capitalization stood at 2.5 billion yuan [2]

Revenue and Profitability - The company's revenue for Q3 2025 was ¥64,314,137.14, representing a 2.60% increase year-over-year, while the year-to-date revenue decreased by 8.56% to ¥200,021,471.55[5] - The net profit attributable to shareholders for Q3 2025 was -¥25,565,959.76, a significant decline of 368.44% compared to the same period last year, with a year-to-date net profit of -¥40,398,114.67, down 993.92%[5] - The basic and diluted earnings per share for Q3 2025 were both -¥0.1452, reflecting a decrease of 368.39% year-over-year, with year-to-date earnings per share at -¥0.2295, down 992.86%[5] - The net loss attributable to the parent company was CNY -23,661,161.79, compared to a profit of CNY 16,736,952.88 in the previous period[17] - Operating profit was recorded at -¥38,388,804.68, a substantial decrease from -¥3,320,491.30 in the prior period[21] - The basic and diluted earnings per share were both reported at -¥0.2295, compared to -¥0.0210 in the previous period, reflecting a deterioration in earnings performance[21] Operating Costs and Expenses - Operating costs increased by 31.36% to ¥156,794,132.55 due to the addition of AI server business in the current period[10] - Total operating costs increased to CNY 230,411,567.02, up 4.0% from CNY 220,696,045.74 year-over-year[19] - Research and development expenses were ¥14,287,394.58, down from ¥18,620,749.38, indicating a reduction in investment in innovation[21] - The company incurred financial expenses of ¥5,395,984.49, an increase from ¥4,957,412.44, primarily due to higher interest expenses[21] Cash Flow and Investments - The company's cash flow from operating activities showed a year-to-date net outflow of -¥36,788,916.03, a decrease of 15.93% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of -¥36,788,916.03, worsening from -¥31,732,542.11 in the previous period[23] - Investment activities resulted in a net cash outflow of -¥14,084,522.42, compared to -¥11,796,796.53 in the prior period, indicating increased investment expenditures[23] - The company raised ¥164,900,000.00 through financing activities, an increase from ¥98,250,720.00 in the previous period, showing improved access to capital[23] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥797,544,165.12, a decrease of 1.32% from the end of the previous year[5] - Total current assets amounted to CNY 253,147,648.77, slightly up from CNY 249,830,978.43 at the start of the quarter[16] - Total liabilities increased to CNY 337,069,742.75 from CNY 308,946,095.60, reflecting a rise of 9.1%[17] - The company's total assets decreased to CNY 797,544,165.12 from CNY 808,223,377.29, a decline of 1.0%[17] - Cash and cash equivalents decreased to CNY 27,830,758.51 from CNY 48,843,383.16, a decline of 43.1%[15] - Short-term borrowings decreased to CNY 104,949,797.22 from CNY 128,134,459.63, a reduction of 18.1%[16] Prepayments and Contract Liabilities - The company reported a significant increase in prepayments, rising by 1173.97% to ¥38,526,698.80, primarily due to increased procurement prepayments[8] - The company reported a significant increase in prepayments, which rose to CNY 38,526,698.80 from CNY 3,024,135.40, indicating a growth of 1,272.5%[15] - The company experienced a 200.95% increase in contract liabilities, reaching ¥34,630,933.57, attributed to an increase in advance payments received[8] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,265, with the largest shareholder holding 38.36% of the shares[12] Inventory and Credit Impairment - Inventory at the end of the quarter was CNY 99,598,057.39, an increase of 5.3% from CNY 94,077,645.27 at the beginning of the period[16] - The company recorded a 68.00% reduction in credit impairment losses, amounting to -¥843,432.47, due to a decrease in accounts receivable[10]

证券代码：002898 证券简称：*ST赛隆 公告编号：2025-086 赛隆药业集团股份有限公司 关于 2025 年前三季度计提减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、本次计提减值准备情况概述 2.本次计提减值准备的资产范围、总金额和计入的报告期间 经过公司及下属子公司对截至2025年9月30日可能存在减值迹象的资产进行 全面清查和减值测试，2025年前三季度计提资产减值准备的范围包括应收账款、 存货及其他应收款，计提资产减值损失686.54万元，计提信用减值损失84.34万 元，具体明细如下表： | 单位：元 | | --- | | 项目 | 计提减值损失金额（转 回以"-"号填列） | 占2024年度经审计归属于上市公 司股东的净利润的比例 | | --- | --- | --- | | 一、资产减值损失 | 6,865,407.78 | 20.71% | | 其中：存货跌价损失 | 6,865,407.78 | 20.71% | | 二、信用减值损失 | 843,432.47 | 2.55% | | 其中：应收账款坏账损失 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-087 赛隆药业集团股份有限公司 1.审议并通过了《关于公司 2025 年第三季度报告的议案》 该事项已经公司第四届董事会审计委员会 2025 年第五次会议审议通过，具 体内容详见同日刊登在巨潮资讯网（www.cninfo.com.cn）上的《2025 年第三季 度报告》（公告编号：2025-088）。 表决结果：表决票数 9 票，赞成 9 票，反对 0 票，弃权 0 票。 三、备查文件 1.第四届董事会第十七次会议决议； 2.董事会审计委员会 2025 年度第五次会议决议。 特此公告。 第四届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 赛隆药业集团股份有限公司（以下简称"公司"）第四届董事会第十七次会 议通知于 2025 年 10 月 24 日以书面方式通过专人送出、传真、电子邮件、即时 通讯相结合的方式送达各位董事。会议于 2025 年 10 月 27 日在湖南省长沙市长 沙县星沙产业基地红枫路 1 号湖南赛隆药业（长沙）有限公司会议 ...

Market Overview - The Shanghai Composite Index closed at 3869.25 points, with a change of 0.10% [1] - The total trading volume of A-shares reached 1,280.495 billion yuan [1] Technical Analysis - A total of 175 A-shares experienced a death cross between the 5-day and 10-day moving averages [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yuanjie Technology: 5-day MA down by 2.50% from the 10-day MA [1] - Shanshan Shares: 5-day MA down by 2.32% from the 10-day MA [1] - Zijian Electronics: 5-day MA down by 2.09% from the 10-day MA [1] Individual Stock Performance - Yuanjie Technology (688498): Increased by 3.59% with a trading turnover of 2.90% [1] - Shanshan Shares (600884): Increased by 0.22% with a trading turnover of 3.13% [1] - Zijian Electronics (301121): Decreased by 0.60% with a trading turnover of 3.19% [1] - Other notable stocks include: - WuXi AppTec (603259): Increased by 2.21% [1] - Fabon (300925): Increased by 1.67% [1] Summary of Stocks with Death Cross - Stocks with a death cross and their respective metrics include: - Yuanjie Technology: 5-day MA at 374.57 yuan, 10-day MA at 384.17 yuan [1] - Shanshan Shares: 5-day MA at 14.17 yuan, 10-day MA at 14.51 yuan [1] - Zijian Electronics: 5-day MA at 48.72 yuan, 10-day MA at 49.76 yuan [1] - The latest prices of these stocks are below their 10-day moving averages, indicating potential bearish trends [1]